Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study

Table 2 Clinicopathologic factors according to treatment response

Characteristic	Incomplete response, N = 141	Response, N = 41	P value2
Age (yr)	60 (57, 63)	60 (52, 67)	> 0.9
Sex			0.3
F	5 (36%)	0 (0%)
M	9 (64%)	4 (100%)
Stage			0.6
I	2 (14%)	2 (50%)
II	5 (36%)	1 (25%)
III	6 (43%)	1 (25%)
IV	1 (7.1%)	0 (0%)
Grade			0.6
G1	1 (7.1%)	0 (0%)
G2	2 (14%)	2 (50%)
G3	10 (71%)	2 (50%)
Gx	1 (7.1%)	0 (0%)
Tumour location			> 0.9
Distal	3 (21%)	1 (25%)
Proximal	10 (71%)	3 (75%)
Whole stomach	1 (7.1%)	0 (0%)
Lauren classification			0.5
Diffuse	10 (71%)	1 (33%)
Intestinal	4 (29%)	2 (67%)
Signet ring cell (present)	9 (64%)	1 (33%)	0.5
H. pylori history			> 0.9
Negative	8 (57%)	2 (50%)
Positive	3 (21%)	1 (25%)
Unknown	3 (21%)	1 (25%)
Smoker			> 0.9
Yes	4 (33%)	2 (50%)
No	4 (33%)	1 (25%)
Ex	4 (33%)	1 (25%)
Smoker (pack years)	13 (0, 40)	36 (25, 42)	0.5
Surgery			> 0.9
Total gastrectomy	10 (71%)	3 (75%)
Distal gastrectomy	3 (21%)	1 (25%)
No resection	1 (7.1%)	0 (0%)

¹Median (IQR); n (%).

²Wilcoxon rank sum test; Fisher's exact test.